Article
Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.
The Lancet. Respiratory medicine - 1 Mar 2014
Ortega Victor E, Hawkins Gregory A, Moore Wendy C, Hastie Annette T, Ampleford Elizabeth J, Busse William W, Castro Mario, Chardon Domingo, Erzurum Serpil C, Israel Elliot, Montealegre Federico, Wenzel Sally E, Peters Stephen P, Meyers Deborah A, Bleecker Eugene R
Abstract excerpt
BACKGROUND: Severe adverse life-threatening events associated with longacting β agonist (LABA) use have caused the US Food and Drug Administration (FDA) to review the safety of these drugs, resulting in a boxed warning and a mandatory safety study in 46 800 patients with asthma. Identification of an at-risk, susceptible subpopulation on the basis of predictive biomarkers is crucial for understanding LABA safety....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.